Log in

LON:VALValiRx Share Price, Forecast & News

GBX 7.12
-0.25 (-3.39 %)
(As of 06/5/2020 04:00 PM ET)
Add
Compare
Today's Range
7.03
Now: GBX 7.13
7.50
50-Day Range
3.50
MA: GBX 7.48
13.13
52-Week Range
2.65
Now: GBX 7.13
68.46
Volume1.20 million shs
Average Volume3.82 million shs
Market Capitalization£1.28 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
ValiRx plc, a biotechnology oncology focused company, engages in developing novel treatments for cancer and associated biomarkers in the United Kingdom. Its proprietary GeneICE technology enables the selective silencing of specific genes by targeted histone deacetylation leading to chromatin condensation. The company's lead drug candidates include VAL201, an anti-cancer therapeutic that is in Phase I/II trials for the treatment of prostate cancer and other indications of hormone induced unregulated growth, including endometriosis; VAL301, a reformulation of VAL201, which is in pre-clinical development for the non-invasive and better tolerated treatment of endometriosis; and VAL401, a reformulation of generic drug Risperidone, which has completed Phase II clinical trials for the treatment of non-small cell lung cancer. Its drug candidates also comprise VAL101, a therapeutic based on GeneICE platform that acts to target and switch off the Bcl-2 gene, a protein that is implicated carcinomas. It has licensing collaborations with Imperial Innovations Group plc, Cancer Research UK, and University College London Hospital. ValiRx plc was incorporated in 2000 and is based in London, the United Kingdom.
Read More
ValiRx logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 1.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.47 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-20-30084416

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Cash FlowGBX 2 per share
Book ValueGBX 42.50 per share

Profitability

Miscellaneous

Employees12
Market Cap£1.28 million
Next Earnings DateN/A
OptionableNot Optionable

Receive VAL News and Ratings via Email

Sign-up to receive the latest news and ratings for VAL and its competitors with MarketBeat's FREE daily newsletter.

ValiRx (LON:VAL) Frequently Asked Questions

How has ValiRx's stock been impacted by COVID-19 (Coronavirus)?

ValiRx's stock was trading at GBX 0.05 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, VAL stock has increased by 15,733.3% and is now trading at GBX 7.13. View which stocks have been most impacted by Coronavirus.

How were ValiRx's earnings last quarter?

ValiRx Plc (LON:VAL) issued its quarterly earnings data on Tuesday, April, 10th. The company reported ($1.90) earnings per share for the quarter, topping analysts' consensus estimates of ($2.60) by $0.70. View ValiRx's earnings history.

Has ValiRx been receiving favorable news coverage?

Media headlines about VAL stock have been trending positive this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. ValiRx earned a media sentiment score of 2.2 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutValiRx.

Who are some of ValiRx's key competitors?

What other stocks do shareholders of ValiRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ValiRx investors own include Petrofac (PFC), Boohoo Group (BOO), ReNeuron Group (RENE), Falanx Group (FLX), Solo Oil (SOLO), Cyanconnode (CYAN), IQE (IQE), Lloyds Banking Group (LLOY), Eckoh (ECK) and Sareum (SAR).

Who are ValiRx's key executives?

ValiRx's management team includes the following people:
  • Dr. Satu Vainikka, Founding Director & CEO (Age 52)
  • Mr. James Gerry Desler, Founding Director & CFO (Age 63)
  • Dr. George Morris, Founding Director & COO (Age 63)
  • Mr. Kevin Alexander, Sec. & Non-Exec. Director (Age 63)
  • Mr. Tarquin Edwards, Head of Investor Relations & Communications

What is ValiRx's stock symbol?

ValiRx trades on the London Stock Exchange (LON) under the ticker symbol "VAL."

How do I buy shares of ValiRx?

Shares of VAL and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is ValiRx's stock price today?

One share of VAL stock can currently be purchased for approximately GBX 7.13.

How big of a company is ValiRx?

ValiRx has a market capitalization of £1.28 million. ValiRx employs 12 workers across the globe.

What is ValiRx's official website?

The official website for ValiRx is www.valirx.com.

How can I contact ValiRx?

ValiRx's mailing address is 3rd Fl, 16 Upper Woburn Place, LONDON, WC1H 0BS, United Kingdom. The company can be reached via phone at +44-20-30084416.

This page was last updated on 6/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.